By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

UCB Inc. et al. v. Aurobindo
Pharma Ltd., et al.
1:13-cv-01210; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Aurobindo Pharma
Ltd.; Aurobindo Pharma USA Inc.

UCB Inc. et al. v. Accord
Healthcare Inc. et al.
1:13-cv-01206; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Accord
Healthcare Inc.; Intas Pharmaceuticals Ltd.

UCB Inc. et al. v. Alembic
Pharmaceuticals Ltd. et al.
1:13-cv-01207; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Alembic
Pharmaceuticals Ltd.; Alembic Ltd.; Alembic Pharma Ltd.

UCB Inc. et al. v. Amneal
Pharmaceuticals LLC et al.
1:13-cv-01208; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Amneal
Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC; Amneal
Pharmaceuticals Co. India Private Ltd.

UCB Inc. et al. v. Apotex
Corp. et al.
1:13-cv-01209; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Apotex Corp.;
Apotex Inc.

UCB Inc. et al. v.
Breckenridge Pharmaceutical Inc. et al.
1:13-cv-01211; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Breckenridge
Pharmaceutical Inc.; Vennoot Pharmaceuticals LLC

UCB Inc. et al. v. Glenmark
Generics Inc. USA et al.
1:13-cv-01212; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Glenmark
Generics Inc. USA; Glenmark Generics Ltd.

UCB Inc. et al. v. Hetero USA
Inc. et al.
1:13-cv-01213; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Hetero USA Inc.;
Hetero Labs Limited Unit V

UCB Inc. et al. v. Mylan
Pharmaceuticals Inc. et al.
1:13-cv-01214; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Mylan
Pharmaceuticals Inc.; Mylan Inc.

UCB Inc. et al. v. Ranbaxy
Laboratories Ltd. et al.
1:13-cv-01215; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Ranbaxy
Laboratories Ltd.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Inc.

UCB Inc. et al. v. Sandoz Inc.
1:13-cv-01216; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendant:  Sandoz Inc.

UCB Inc. et al. v ScieGen
Pharmaceuticals Inc. et al.
1:13-cv-01217; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  ScieGen
Pharmaceuticals Inc.; Bactolac Pharmaceutical Inc.

UCB Inc. et al. v Sun Pharma
Global FZE et al.
1:13-cv-01218; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Sun Pharma
Global FZE; Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries
Inc.

UCB Inc. et al. v. Watson
Laboratories Inc. – Florida et al.
1:13-cv-01219; filed July 10,
2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Watson
Laboratories Inc. – Florida; Watson Pharma Inc.; Actavis Inc.

UCB Inc. et al. v. Zydus
Pharmaceuticals (USA) Inc. et al.
1:13-cv-01220; filed
July 10, 2013 in the District Court of Delaware

• Plaintiffs:  UCB Inc.; UCB
Pharma GmbH; Research Corporation Technologies Inc.; Harris FRC Corp.
• Defendants:  Zydus
Pharmaceuticals (USA) Inc.; Cadila Healthcare Ltd.

The complaints in these cases
are substantially identical.  Infringement
of U.S. Patent No. RE38,551 ("Anticonvulsant Enantiomeric Amino Acid
Derivatives," issued July 6, 2004) following a Paragraph IV certification
as part of defendants' filing of an ANDA to manufacture a generic version of
UCB's Vimpat® (lacosamide, used as adjunctive therapy in the treatment of
partial-onset seizures in people with epilepsy aged 17 years and older).  View the Aurobindo
complaint here.

Par Pharmaceutical, Inc. et
al. v. Takeda Pharmaceutical Co., Ltd. et al.
3:13-cv-03151; filed July 9,
2013 in the Northern District of California

• Plaintiffs:  Par
Pharmaceutical, Inc.; Handa Pharmaceuticals, LLC
• Defendants:  Takeda
Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.; Takeda
Pharmaceuticals America, Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Declaratory judgment of
invalidity and/or non-infringement of U.S. Patent No. 8,461,187 ("Multiple
PPI Dosage Form," issued June 11, 2013) in conjunction with Par's filing
of an ANDA to manufacture a generic version of Takeda's Dexilant®
(dexlansoprazole, used for the treatment of all grades of erosive esophagitis,
maintaining healing of esophagitis, and treating heartburn associated with
symptomatic non-erosive gastroesophageal reflux disease).  View the complaint here.

University of Utah Research
Foundation et al. v. Ambry Genetics
2:13-cv-00640; filed July 9,
2013 in the District Court of Utah

• Plaintiffs:  University of
Utah Research Foundation; Trustees of the University of Pennsylvania; HSC
Research and Development Limited Partnership; Endorecherche; Myriad Genetics
• Defendant:  Ambry Genetics

Infringement of U.S. Patent
Nos. 5,709,999 ("Linked breast and ovarian cancer susceptibility gene,"
issued January 20, 1998), 5,747,282 ("17Q-linked breast and ovarian cancer
susceptibility gene," issued May 5, 1998), 5,753,441 ("170-linked
breast and ovarian cancer susceptibility gene," issued May 19, 1998), 5,837,492 ("Chromosome 13-linked breast cancer susceptibility gene,"
issued November 17, 1998), 6,033,857 (same title, issued March 7, 2000), 5,654,155 ("Consensus sequence of the human BRCA1 gene," issued
August 5, 1997), 5,750,400 ("Coding sequences of the human BRCA1 gene,"
issued May 12, 1998), 6,051,379 ("Cancer susceptibility mutations of BRCA2,"
issued April 18, 2000), 6,951,721 ("Method for determining the haplotype
of a human BRCA1 gene," issued October 5, 2005), and 7,250,497 ("Large
deletions in human BRCA1 gene and use thereof," issued July 31, 2007)
based on Ambry's offer of laboratory services, including clinical diagnostic
and genomic services, including testing and analysis of BRCA1 and BRCA2
genes.  View the complaint here.